XML 35 R24.htm IDEA: XBRL DOCUMENT v3.21.2
Fair value of financial instruments and marketable securities - (Tables)
9 Months Ended
Sep. 30, 2021
Fair Value Disclosures [Abstract]  
Schedule of financial assets and liabilities that are required to be measured at fair value on a recurring basis

September 30, 2021

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

472,338

$

$

472,338

$

Marketable securities - equity investments

$

205,787

$

205,787

$

$

ClearPoint Equity Investments

$

22,979

$

22,979

$

$

ClearPoint convertible debt security

$

31,306

$

$

31,306

$

Contingent consideration payable- development and regulatory milestones

$

140,200

$

$

$

140,200

Contingent consideration payable- net sales milestones and royalties

$

111,800

$

$

$

111,800

December 31, 2020

 

 

Quoted prices

 

Significant

 

 

in active

 

other

 

Significant

 

markets for

 

observable

 

unobservable

 

identical assets

 

inputs

 

inputs

    

Total

    

(level 1)

    

(level 2)

    

(level 3)

Marketable securities - available for sale

$

894,838

$

$

894,838

$

ClearPoint Equity Investments

$

20,503

$

20,503

$

$

ClearPoint convertible debt security

$

29,252

$

$

29,252

$

Contingent consideration payable- development and regulatory milestones

$

139,200

$

$

$

139,200

Contingent consideration payable- net sales milestones and royalties

$

101,200

$

$

$

101,200

Summary of marketable securities accounted for as available-for-sale debt securities

September 30, 2021

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Commercial paper

$

109,890

$

20

$

$

109,910

Corporate debt securities

 

281,467

 

351

 

(37)

 

281,781

Asset-backed securities

 

20,704

 

45

 

(1)

 

20,748

Government obligations

59,883

20

 

(4)

59,899

Total

$

471,944

$

436

$

(42)

$

472,338

December 31, 2020

 

Amortized

 

Gross Unrealized

    

Cost

    

Gains

    

Losses

    

Fair Value

Commercial paper

$

276,855

$

19

$

(37)

$

276,837

Corporate debt securities

 

474,030

 

1,658

 

(29)

 

475,659

Asset-backed securities

 

28,681

 

210

 

(3)

 

28,888

Government obligations

113,372

88

(6)

113,454

Total

$

892,938

$

1,975

$

(75)

$

894,838

Summary of unrealized losses and fair values of available-for-sale debt securities in a continuous unrealized loss position

September 30, 2021

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than 12 months

Total

    

Unrealized losses

    

Fair Value

    

Unrealized losses

    

Fair Value

    

Unrealized losses

    

Fair Value

Corporate debt securities

(37)

78,272

(37)

78,272

Asset-backed securities

 

(1)

 

499

 

 

 

(1)

 

499

Government obligations

(4)

19,926

(4)

19,926

Total

$

(42)

$

98,697

$

$

$

(42)

$

98,697

December 31, 2020

 

Securities in an unrealized loss

 

Securities in an unrealized loss

 

 

position less than 12 months

 

position greater than 12 months

Total

    

Unrealized losses

    

Fair Value

    

Unrealized losses

    

Fair Value

    

Unrealized losses

    

Fair Value

Commercial paper

$

(37)

129,630

(37)

129,630

Corporate debt securities

(29)

102,426

(29)

102,426

Asset-backed securities

 

(3)

 

1,830

 

 

 

(3)

 

1,830

Government obligations

(6)

27,084

(6)

27,084

Total

$

(75)

$

260,970

$

$

$

(75)

$

260,970

Schedule of marketable securities on the balance sheet

September 30, 2021

 

Less Than

 

More Than

    

12 Months

    

12 Months

Commercial paper

$

109,910

$

Corporate debt securities

 

154,067

 

127,714

Asset-backed securities

 

8,881

 

11,867

Government obligations

49,608

10,291

Total

$

322,466

$

149,872

December 31, 2020

 

Less Than

 

More Than

    

12 Months

    

12 Months

Commercial paper

$

276,837

$

Corporate debt securities

 

240,139

 

235,520

Asset-backed securities

 

6,363

 

22,525

Government obligations

65,524

47,930

Total

$

588,863

$

305,975

Summary of changes in the fair value of the Company's Level 3 valuation for contingent consideration payable

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

milestones

    

Beginning balance as of December 31, 2020

$

139,200

$

101,200

Additions

 

 

Change in fair value

 

1,000

 

10,600

Payments

Ending balance as of September 30, 2021

$

140,200

$

111,800

Level 3 liabilities

Contingent consideration payable-

Contingent consideration payable-

development and regulatory

net sales milestones and royalties

    

    

milestones

    

Beginning balance as of December 31, 2019

$

290,500

$

65,800

Additions

 

 

Change in fair value

 

(13,120)

 

30,100

Payments

Rights Exchange settlement

(139,180)

Ending balance as of September 30, 2020

$

138,200

$

95,900

Fair Value Measurement Inputs and Valuation Techniques

September 30, 2021

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$140,200

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $381 million
25% - 94%
1.6% - 4.7%
2022 - 2028

Contingent considerable payable- net sales
milestones and royalties

$111,800

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $150 million
25% - 94%
2% - 6%
11.0%
2022 - 2040

December 31, 2020

    

Fair Value

    

Valuation Technique

    

Unobservable Input

    

Range

Contingent consideration payable-
development and regulatory milestones

$139,200

 

 Probability-adjusted discounted cash flow 

 

Potential development and regulatory milestones
Probabilities of success
Discount rates
Projected years of payments

$0 - $381 million
25% - 94%
2.2% - 4.5%
2021 - 2028

Contingent considerable payable- net sales
milestones and royalties

$101,200

 

Option-pricing model with Monte Carlo simulation  

 

Potential net sales milestones
Probabilities of success
Potential percentage of net sales for royalties
Discount rate
Projected years of payments

$0 - $150 million
25% - 94%
2% - 6%
11.5%
2022 - 2040